Biopharmaceutical company developing recombinant alkaline phosphatase therapeutics
Location: Netherlands, Utrecht
Employees: 201-500
Total raised: $188.81M
Founded date: 2000
Investors 8
Funding Rounds 3
| Date | Series | Amount | Investors |
| 16.07.2019 | - | $133M | - |
| 11.09.2014 | - | $15.81M | - |
| 13.09.2011 | Series D | $40M | - |
Mentions in press and media 21
| Date | Title | Description |
| 07.01.2021 | AM-Pharma Announces Enrollment and Financing of COVID-19 Cohort in Phase III REVIVAL Trial | |
| 03.04.2020 | Daily funding roundup - April 2nd, 2020 | Jenny Life raised $3.5M; SteadyMD closed $6M; Zucara Therapeutics landed $21M Atmosphere Atmosphere is a streaming TV service for businesses. Atmosphere has raised $5 million in fresh Series A funding that brings the total round to $14 mill... |
| 01.04.2020 | AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI | |
| 31.03.2020 | AM-Pharma recibe €47 millones de Cowen Healthcare y del European Investment Bank | 31/03/2020 Nota de prensa AM-PHARMA RECIBE €47 MILLONES DE COWEN HEALTHCARE Y DEL EUROPEAN INVESTMENT BANK. • €23m [US$25.5m] equity provided mainly by US-based Cowen Healthcare Investments • €24m [US$26.5m] finance facility provided by ... |
| 24.01.2020 | Dutch startups raised €1.5B in 2019: What about the future unicorns of the Netherlands | The Netherlands is one of the largest startup ecosystems in Europe, thanks to the ample innovation and unprecedented digital infrastructure in the country. It is expected that the Netherlands would deliver a couple of billion-dollar worth c... |
| 08.10.2019 | European tech startups shining: 10 record-breaking funding rounds of Q3 2019 | European venture capital funding is skyrocketing and has reached a milestone in the most recent quarter. As per a new study by Dealroom, European startups (excluding Israel) have raised €8.7 billion, which is a 44% increase as compared to t... |
| 16.07.2019 | BioDiscovery co-leads $133 million Financing in AM-Pharma B.V. | |
| 16.07.2019 | Free of Pfizer, AM-Pharma raises €116M for phase 3 | AM-Pharma has raised €116 million ($131 million) to run a pivotal clinical trial in sepsis-associated acute kidney injury (SA-AKI). The financing sets AM-Pharma up to advance recAP independently now that Pfizer has turned down its option to... |
| 16.07.2019 | AM-Pharma Raises Record Financing of €116m [$133m] for Phase III Trial in Acute Kidney Injury | Bunnik, The Netherlands – AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human Alkaline Phosphat... |
| 16.07.2019 | Ysios Capital participa en la ronda de €116M ($133M) de su participada AM-Pharma | 16/07/2019 Nota de prensa YSIOS CAPITAL PARTICIPA EN LA RONDA DE €116 MILLONES ($133 MILLONES) DE SU PARTICIPADA AM-PHARMA. AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development... |
Show more